

Attorney Docket No. 5515.214-US  
Serial No. 09/886,311  
Filed: June 21, 2001  
Inventors: Knudsen et al.  
Via Facsimile No.: 571-273-8300

RECEIVED  
CENTRAL FAX CENTER  
DEC 22 2006

**REMARKS**

Claims 92, 96-99, 104-106, and 122-123 will be pending upon entry of the present amendment. Applicants have limited the claims to derivatives of exendin-4 or a fragment thereof, subject matter that the Office Action indicates to be enabled. As the present amendment should require no additional search by the Office and is believed to place the application in condition for allowance, its entry is respectfully requested.

As requested in the Office Action, a new Abstract is presented herein.

**REJECTION OF THE CLAIMS UNDER 35 U.S.C. 112, FIRST PARAGRAPH**

The Examiner rejected claims 92-93, 96-99, 104-106 and 122-135 (now 92, 96-99, 104-106, and 121-123) under 112, 1<sup>st</sup> paragraph.


Applicants submit that this rejection has been obviated by appropriate amendment. Page 3 of the 29 June 06 Office Action states the above-identified application is enabled for derivatives of exendin-4 or a fragment thereof. The claims are now limited to derivatives of exendin-4 or a fragment thereof. Withdrawal of this rejection is therefore respectfully requested.

Attorney Docket No. 5515.214-US  
Serial No. 09/886,311  
Filed: June 21, 2001  
Inventors: Knudsen et al.  
Via Facsimile No.: 571-273-8300

It is believed that the claims as presented are in condition for allowance, and a  
determination to that effect is earnestly solicited.

Respectfully submitted,

Date: December 22, 2006

  
Richard W. Bork, Reg. No. 36,459  
Novo Nordisk, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5800

Use the following customer number for all correspondence regarding this application

**23650**

PATENT TRADEMARK OFFICE